Horizon snaps up rare disease drugs, pipeline, in $800M Raptor buyout
Horizon Pharma has bagged Raptor Pharmaceuticals $RPTP and a pair of rare disease drugs on the market — along with a multi-drug pipeline — in
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
